Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 144

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9C
Chunk 144
---
 goals at
    the time of the change of control, prorated based on the number of full months elapsed in the performance period.

    ●
    All
    unvested dividend equivalent units will vest (to the same extent as the award granted in tandem with such units) and be paid.

    ●
    All
    other unvested awards will vest and any amounts payable will be paid in cash.

Term
of Plan

Unless
earlier terminated by our board of directors, the 2023 Omnibus Plan will terminate on, and no further awards may be granted, after the
tenth (10th) anniversary of its effective date.

Termination
and Amendment of Plan

Our
board of directors or the Administrator may amend, alter, suspend, discontinue, or terminate the 2023 Omnibus Plan at any time, subject
to the following limitations:

    ●
    Our
    board of directors must approve any amendment to the 2023 Omnibus Plan if we determine such approval is required by prior action
    of our board of directors, applicable corporate law, or any other applicable law;

    ●
    Stockholders
    must approve any amendment to the 2023 Omnibus Plan, which may include an amendment to materially increase the number of shares reserved
    under the 2023 Omnibus Plan, if we determine that such approval is required by Section 16 of the Exchange Act, the Code, the listing
    requirements of any principal securities exchange or market on which the shares are then traded, or any other applicable law; and

    ●
    Stockholders
    must approve any amendment to the 2023 Omnibus Plan that would diminish the protections afforded by the participant award limits
    or repricing and backdating prohibitions.

Amendment,
Modification, Cancellation and Disgorgement of Awards

Subject
to the requirements of the 2023 Omnibus Plan, the Administrator may modify or amend any award or waive any restrictions or conditions
applicable to any award or the exercise of the award, or amend, modify, or cancel any terms and conditions applicable to any award, in
each case, by mutual agreement of the Administrator and the participant or any other person that may have an interest in the award, so
long as any such action does not increase the number of shares of common stock issuable under the 2023 Omnibus Plan.

We
do not need to obtain participant (or other interested party) consent for any such